ASX Growth Companies With High Insider Ownership For November 2024

In the midst of a challenging trading session, the ASX200 closed down 0.7% at 8,359 points, largely impacted by a sell-off in energy stocks and banks following tariff threats from Donald Trump. Despite these headwinds, certain sectors like Staples and Information Technology showed resilience, highlighting the importance of strategic stock selection—particularly companies with strong growth potential and high insider ownership that can offer stability and confidence to investors during volatile times.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
SKS Technologies Group (ASX:SKS)	32.4%	24.8%
Catalyst Metals (ASX:CYL)	14.8%	33.1%
Acrux (ASX:ACR)	19.5%	91.6%
AVA Risk Group (ASX:AVA)	15.7%	77.3%
Newfield Resources (ASX:NWF)	31.5%	72.1%
Findi (ASX:FND)	34.8%	71.5%
Hillgrove Resources (ASX:HGO)	10.4%	66.5%
Pointerra (ASX:3DP)	20.8%	126.4%
Plenti Group (ASX:PLT)	12.8%	120.1%
Brightstar Resources (ASX:BTR)	16.2%	84.6%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Aussie Broadband (ASX:ABB)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aussie Broadband Limited offers telecommunications and technology services in Australia, with a market capitalization of A$1.04 billion.

Operations: The company's revenue is primarily derived from its Residential segment at A$585.07 million, followed by Wholesale at A$159.73 million, Business at A$96.97 million, Enterprise and Government at A$88.04 million, and Symbio Group at A$69.93 million.

Insider Ownership: 11.1%

Aussie Broadband demonstrates potential as a growth company with high insider ownership, despite some challenges. Its earnings are forecast to grow significantly at 23.2% annually, surpassing the Australian market's average. However, revenue growth is expected to be moderate at 8.4% per year and below the desired benchmark for rapid expansion. Insider activity shows more buying than selling in recent months, indicating confidence from insiders despite past shareholder dilution and low future return on equity forecasts (11%).

• Delve into the full analysis future growth report here for a deeper understanding of Aussie Broadband.
• Upon reviewing our latest valuation report, Aussie Broadband's share price might be too pessimistic.

Accent Group (ASX:AX1)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand with a market capitalization of A$1.29 billion.

Operations: The company's revenue is primarily derived from its retail segment, generating A$1.27 billion, complemented by A$463.20 million from wholesale activities in Australia and New Zealand.

Insider Ownership: 14.8%

Accent Group shows potential for growth with high insider ownership, as insiders have been buying more shares than selling recently. Earnings are projected to grow at 14.7% annually, outpacing the Australian market's average. However, profit margins have decreased and dividends are not well covered by earnings. Recent board changes include appointing Dave Forsey as an Independent Non-Executive Director, which may enhance strategic direction given his extensive retail experience.

• Click here to discover the nuances of Accent Group with our detailed analytical future growth report.
• Our expertly prepared valuation report Accent Group implies its share price may be lower than expected.

Clinuvel Pharmaceuticals (ASX:CUV)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$644.81 million.

Operations: The company's revenue is primarily derived from its Biopharmaceutical Sector, amounting to A$88.18 million.

Insider Ownership: 10.4%

Clinuvel Pharmaceuticals stands out with substantial insider ownership, aligning management interests with shareholders. The company's earnings and revenue are forecasted to grow significantly, at 26.16% and 21.4% annually, respectively, outpacing the broader Australian market. Recent strategic moves include filing a New Drug Submission in Canada for SCENESSE® and exploring M&A opportunities due to strong cash reserves. Despite these growth prospects, Clinuvel's return on equity is expected to remain relatively low at 19.9%.

• Click to explore a detailed breakdown of our findings in Clinuvel Pharmaceuticals' earnings growth report.
• Our valuation report unveils the possibility Clinuvel Pharmaceuticals' shares may be trading at a discount.

Seize The Opportunity

• Reveal the 91 hidden gems among our Fast Growing ASX Companies With High Insider Ownership screener with a single click here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com